List of Excipients in Branded Drug DELSYM

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
ATLANTIC BIOLOGICALS CORP	DELSYM	dextromethorphan	17856-0172	ANHYDROUS CITRIC ACID
ATLANTIC BIOLOGICALS CORP	DELSYM	dextromethorphan	17856-0172	D&C RED NO. 33
ATLANTIC BIOLOGICALS CORP	DELSYM	dextromethorphan	17856-0172	EDETATE DISODIUM
ATLANTIC BIOLOGICALS CORP	DELSYM	dextromethorphan	17856-0172	ETHYLCELLULOSE

Delsym Excipient Strategy and Commercial Opportunities

Last updated: August 22, 2026

Delsym is an extended-release oral suspension containing dextromethorphan polistirex, an ion-exchange resin complex that releases dextromethorphan over approximately 12 hours. Its commercial differentiation depends more on the resin-controlled release system, taste masking, suspension stability, dose accuracy, and consumer positioning than on the dextromethorphan molecule itself. The strongest opportunities are private-label extended-release cough products, sugar-reduced formulations, pediatric-friendly delivery, preservative alternatives, and global OTC products using comparable ion-exchange technology.

What is Delsym and how does its excipient system work?

Delsym uses dextromethorphan polistirex rather than immediate-release dextromethorphan hydrobromide. The active complex is designed to slow drug release in the gastrointestinal tract and reduce the frequency of administration. The labeled product is an oral suspension marketed for 12-hour cough relief.[1]

The formulation has four functional excipient requirements:

1. Maintain the drug-resin complex during storage and dosing.
2. Keep the suspension physically uniform.
3. Mask the bitter taste of dextromethorphan.
4. Deliver a reproducible dose from a viscous liquid vehicle.

The commercial formulation is therefore a drug-delivery system, not merely a flavored syrup.

What is dextromethorphan polistirex?

Dextromethorphan polistirex is a complex of dextromethorphan with a sulfonated, cross-linked polystyrene ion-exchange resin. The resin binds the cationic drug and controls its release through ion exchange in gastrointestinal fluids.

This approach can provide:

• Extended drug residence in the dosage form
• Reduced dosing frequency
• Taste masking
• A suspension-based pediatric delivery format
• Differentiation from immediate-release dextromethorphan liquids

The resin is the central functional excipient or excipient-like delivery component. Conventional syrup excipients support the product but do not create its primary duration advantage.

What excipients are used in Delsym?

Delsym labeling identifies a conventional liquid-suspension excipient system that includes viscosity modifiers, sweeteners, preservatives, pH-control agents, solvents or humectants, colorants, and purified water. Exact inactive ingredients can vary by product presentation, flavor, strength, and market.

Public labeling for Delsym products has identified excipient classes and ingredients such as:

Excipient function	Examples associated with Delsym-type formulations	Commercial role
Suspending or rheology control	Xanthan gum and related polymeric stabilizers	Limits settling and supports dose uniformity
Resin or polymer processing	Ethylcellulose or comparable polymeric materials	Supports controlled-release and physical stability
Sweetening	Sucrose, high-fructose corn syrup, or other sweeteners	Improves palatability and consumer acceptance
Humectancy and mouthfeel	Glycerin, propylene glycol	Supports texture, solubilization, and sensory performance
Preservation	Methylparaben or another antimicrobial system	Controls microbial growth in a multidose liquid
Buffering and pH control	Citric acid, sodium citrate	Maintains formulation pH and taste profile
Chelation	Disodium EDTA	Supports preservative performance and stability
Appearance	FD&C colorants	Provides product identification and flavor differentiation
Vehicle	Purified water	Continuous liquid phase

The current package insert and DailyMed entry should control any formulation, labeling, or regulatory assessment because inactive ingredients can differ among Delsym variants.[1]

Which excipients are most important to Delsym performance?

The most commercially important excipients are the suspending polymer, the resin-related controlled-release components, the sweetener system, and the preservative system.

A suspension that settles rapidly can produce underdosing at the beginning of the bottle and overdosing near the end. Excessive viscosity creates poor pourability and dosing difficulty. Insufficient viscosity reduces physical stability. The formulation must balance both properties.

Taste masking also has two layers. The resin can reduce immediate exposure of dextromethorphan to taste receptors, while sweeteners, flavors, and viscosity modifiers improve the residual mouthfeel. An ion-exchange complex with poor release control can produce a bitter initial taste or inconsistent drug release.

What formulation patents protect Delsym?

Delsym's principal technical differentiation is associated with controlled-release dextromethorphan resin complexes and oral suspension technology. Publicly available product information does not establish a current, Delsym-specific, unexpired patent barrier that would prevent development of a therapeutically equivalent extended-release dextromethorphan suspension.

The relevant intellectual-property categories include:

• Dextromethorphan-ion-exchange resin complexes
• Particle-size and loading characteristics of the resin
• Controlled-release oral suspensions
• Taste-masked cough formulations
• Suspension rheology and dose uniformity
• Flavor and preservative systems
• Manufacturing processes for drug-resin complexes

Many foundational ion-exchange resin and dextromethorphan controlled-release concepts originated years ago. The commercial risk today is more likely to arise from formulation execution, regulatory equivalence, trade secrets, trademarks, and manufacturing know-how than from a single blocking composition patent.

How strong is the Delsym patent estate?

The patent estate appears more vulnerable to design-around than a modern small-molecule product protected by a dense portfolio of composition, formulation, method-of-use, and manufacturing patents.

A potential entrant could pursue:

• A different sulfonated ion-exchange resin
• A different cross-link density
• A distinct drug-loading ratio
• Alternative particle-size distribution
• A separate suspension polymer system
• A different sweetener and preservative architecture
• A new flavor and dosage-device combination

The technical challenge is proving equivalent release, stability, dose uniformity, and clinical performance. A design-around that changes the resin system may require substantial formulation and comparative testing even if no blocking patent remains.

When does Delsym lose exclusivity?

Delsym does not have the exclusivity profile of a prescription drug approved through a conventional NDA with patent and regulatory exclusivity periods. It is an OTC product governed primarily by the FDA OTC drug framework for cough and cold products containing dextromethorphan.[2]

The practical exclusivity position is:

Exclusivity category	Delsym position
New chemical entity exclusivity	Not applicable
Prescription NDA exclusivity	Not applicable to the marketed OTC product
Biosimilar exclusivity	Not applicable
Hatch-Waxman Paragraph IV pathway	Generally not applicable absent an Orange Book-listed NDA patent
OTC monograph eligibility	Relevant, subject to applicable conditions
Trademark and trade-dress protection	Commercially relevant
Formulation know-how	Potentially relevant but not publicly defined
Manufacturing know-how	Potentially relevant
Market exclusivity	Dependent on brand recognition, distribution, and execution

Delsym can face competition without a formal patent challenge. Private-label and branded competitors may enter with products using dextromethorphan in immediate-release or extended-release presentations, subject to applicable FDA requirements.

What is the Orange Book status of Delsym?

Delsym is not ordinarily evaluated through the Orange Book framework used for prescription and certain approved over-the-counter drug products. OTC monograph products generally do not create the same Orange Book patent-listing and Paragraph IV litigation structure as an NDA product.[3]

This means:

• A conventional Orange Book patent listing is not the primary competitive barrier.
• A generic applicant would not normally challenge Delsym through a standard Paragraph IV certification to a Delsym patent listing.
• FDA compliance under the OTC pathway and product-specific approval requirements is more important.
• Trademark, trade dress, formulation know-how, and manufacturing controls remain relevant.

A company seeking to commercialize an equivalent product must assess whether its product fits the applicable OTC monograph conditions or requires an NDA, 505(b)(2) application, or another FDA pathway.

Are there Paragraph IV challenges to Delsym?

No standard Paragraph IV challenge is established as the defining route for Delsym competition. Paragraph IV litigation is generally tied to patents listed in the Orange Book for an approved drug application. Delsym's OTC status does not create the same automatic framework.

Competitive entry is more likely to involve:

• OTC monograph compliance
• A product-specific FDA application
• Labeling review
• Demonstration of quality and stability
• Comparative release and performance testing
• Trademark clearance
• Contract manufacturing and supply qualification

The absence of a conventional Paragraph IV pathway can reduce litigation certainty for both the incumbent and entrant. It also means that commercial execution can become the primary source of competitive advantage.

What FDA regulatory pathway applies to Delsym competitors?

A dextromethorphan product may be marketed under the FDA OTC monograph system if it meets the applicable conditions for cough suppressant products. The FDA's OTC Monograph M012 covers certain internal analgesic, antipyretic, and antirheumatic products, while cough suppressant regulation has historically been addressed through applicable OTC cough and cold rules and monograph conditions.[2,4]

An extended-release dextromethorphan polistirex suspension may raise issues that are not present for a simple immediate-release syrup:

• Whether the active ingredient form is covered
• Whether the dosage form and dosing interval conform to the monograph
• Whether the product's release profile is adequately controlled
• Whether pediatric dosing and warnings comply with FDA requirements
• Whether the product requires an approved application rather than monograph marketing

A sponsor should not assume that a formulation is monograph-eligible solely because dextromethorphan is a recognized OTC active ingredient.

Does a Delsym-equivalent product need an ANDA?

Not necessarily. An ANDA is generally associated with a reference listed drug approved under an NDA or ANDA and is not the default route for a monograph OTC product. The applicable pathway depends on the legal status of the target product and the proposed active ingredient, dosage form, claims, and release characteristics.

A materially different extended-release formulation may require an NDA or 505(b)(2)-type strategy if the product falls outside the OTC monograph framework.

What formulation opportunities exist for Delsym competitors?

Sugar-reduced and diabetic-friendly formulations

Traditional cough syrups often rely on sucrose or high-fructose corn syrup. A sugar-reduced or sugar-free Delsym-type product could target consumers seeking lower sugar intake, provided the replacement system preserves:

• Suspension stability
• Taste masking
• Mouthfeel
• Microbial control
• Dose accuracy
• Shelf life

Polyols, high-intensity sweeteners, soluble fibers, and glycerin-based systems are potential tools. Each introduces sensory, gastrointestinal, or stability trade-offs.

Preservative alternatives

Multidose aqueous suspensions require robust microbiological control. A product using a different preservative system or a validated preservative-free package could differentiate on consumer perception, but the technical burden is high.

Potential approaches include:

• Alternative preservative combinations
• Lower-water-activity vehicles
• Single-dose sachets
• Unit-dose cups
• Metered liquid-dosing devices
• Packaging with reduced microbial ingress

Packaging-based preservation can create a stronger commercial proposition than simply replacing methylparaben.

Improved pediatric delivery

Delsym's suspension format is well suited to pediatric use, but pediatric products require careful control of taste, viscosity, dosing devices, and age-specific labeling. Opportunities include:

• Smaller dose volumes
• Oral syringes with improved graduation
• Unit-dose packaging
• Berry, grape, or other child-preferred flavors
• Lower-viscosity pourable systems
• Reduced dye or dye-free options

The FDA has emphasized the importance of age-appropriate dosing and safety labeling for cough and cold products, particularly in young children.[5]

Dye-free and allergen-positioned products

A dye-free presentation can appeal to parents and consumers who avoid synthetic colorants. The opportunity is commercially credible, but color removal must not compromise product identification, flavor coding, or consumer acceptance.

Other positioning opportunities include:

• No artificial color
• Lower sugar
• Alcohol-free
• Gluten-free where supportable
• Reduced excipient count
• Vegetarian or vegan-compatible excipient sourcing

These claims require substantiation and careful label review.

Longer-lasting or twice-daily alternatives

The core Delsym proposition is 12-hour dosing. A competitor could seek a longer interval, but extending release increases regulatory and technical complexity. The product would need a reliable release profile, appropriate exposure, and clear dosing instructions.

A more practical opportunity is to match the 12-hour profile while improving:

• Taste
• Dose volume
• Shakeability
• Pourability
• Stability
• Packaging convenience

What manufacturing and IP barriers affect Delsym competition?

The active ingredient is widely known, but the product requires specialized formulation and process control. Important manufacturing barriers include:

• Reproducible loading of dextromethorphan onto the resin
• Control of resin particle size
• Prevention of drug migration during storage
• Uniform distribution in the suspension
• Control of viscosity across temperature ranges
• Preservation of microbiological quality
• Consistent release testing
• Scale-up from laboratory mixing to commercial batch production

A sponsor may be able to avoid a patent claim yet still face substantial process development. The most valuable know-how may involve resin pretreatment, drug-loading conditions, mixing order, shear exposure, pH adjustment, and filling controls.

Which companies are challenging Delsym?

Competition is likely to come from three groups:

1. Branded OTC manufacturers selling dextromethorphan products.
2. Retailer-owned and private-label manufacturers.
3. Contract development and manufacturing organizations offering extended-release suspension platforms.

The competitive set includes immediate-release dextromethorphan liquids, capsules, lozenges, and extended-release formulations. Products do not need to replicate Delsym's resin technology to compete for the same cough-suppressant occasion.

The strongest commercial threat is a lower-priced extended-release product with comparable taste, dosing frequency, and retail distribution. A private-label product can pressure Delsym without infringing a Delsym trademark or copying its trade dress.

What licensing deals could create commercial opportunities?

Potential licensing targets include:

• Ion-exchange resin platforms
• Taste-masking technologies
• Pediatric liquid formulation platforms
• Preservative-free multidose packaging
• Oral suspension manufacturing processes
• Dosing-device technology
• Regional OTC brands seeking U.S. or international entry

A platform owner could license resin technology to a consumer-health company while retaining rights for prescription or veterinary products. A brand owner could license an established dextromethorphan suspension to a retailer or regional manufacturer.

The most attractive deal structure would likely combine formulation know-how, regulatory documentation, manufacturing transfer, and geographic rights. A bare patent license would have less value if foundational claims are expired or readily designed around.

How does Delsym compare with immediate-release dextromethorphan products?

Attribute	Delsym-type extended-release suspension	Immediate-release dextromethorphan product
Active form	Dextromethorphan polistirex or comparable controlled-release complex	Usually dextromethorphan hydrobromide
Dosing frequency	Approximately every 12 hours	More frequent dosing
Dosage form	Oral suspension	Syrup, capsule, lozenge, or tablet
Taste-masking requirement	High	High, particularly for liquids
Formulation complexity	High	Moderate
Resin technology	Central to performance	Usually absent
Private-label opportunity	Attractive but technically demanding	Broad and easier to manufacture
Main differentiation	Duration, suspension, pediatric usability	Price, flavor, format, and distribution

Delsym's advantage is dosing convenience. Immediate-release competitors can compete on price, portability, and dosage-form variety.

What revenue exposure does Delsym have to excipient changes?

Excipient changes can affect revenue through consumer acceptance, manufacturing yield, product complaints, and regulatory review. High-risk changes include:

• Replacing the suspending polymer
• Changing the resin or resin particle size
• Removing the primary sweetener
• Changing the preservative
• Reducing viscosity
• Changing flavor or color
• Altering the container-closure system

A low-risk opportunity generally involves a secondary excipient change that preserves the validated release, stability, taste, and microbiological profile. A high-value reformulation would improve consumer positioning without changing the product's central 12-hour performance claim.

What generic launch risks exist for Delsym?

A Delsym competitor could launch through an OTC-compliant pathway or an approved application, but commercial success depends on more than active-ingredient availability.

Key launch risks are:

• Failure to reproduce the release profile
• Inadequate suspension uniformity
• Bitter taste after storage
• Poor dose-device compatibility
• Microbial contamination
• Inadequate pediatric acceptability
• Retailer resistance to a new cough brand
• Trademark or trade-dress disputes
• Supply constraints for specialized resin
• Insufficient stability data

The most defensible commercial position is a formulation that combines comparable duration with a clear consumer benefit, such as lower sugar, dye-free presentation, better dosing accuracy, or improved portability.

Key Takeaways

• Delsym's commercial identity is built on dextromethorphan polistirex and 12-hour controlled release.
• The resin and suspension system are more important than ordinary syrup excipients.
• Public regulatory information does not establish a conventional Orange Book or Paragraph IV barrier as the main exclusivity issue.
• The strongest opportunities are sugar-reduced, dye-free, pediatric-friendly, preservative-alternative, and private-label products.
• Manufacturing know-how may be more important than live blocking patents.
• A successful competitor must match release, taste, stability, dose uniformity, and consumer usability.
• Licensing value is highest for integrated resin, formulation, manufacturing, and regulatory packages.

FAQs About Delsym Excipient and Commercial Strategy

Can a company replace the Delsym resin with another controlled-release excipient?

Yes, but the replacement must deliver comparable drug release, stability, taste masking, and dose uniformity. A different resin or polymer can support a design-around, but it may require substantial formulation and regulatory development.

Is dextromethorphan polistirex protected by a current composition patent?

Public product information does not establish a currently blocking, Delsym-specific composition patent. A complete freedom-to-operate analysis would require a claim-level review of relevant U.S. and foreign patent families.

Can Delsym be reformulated without changing its FDA status?

Not always. Changes to the active complex, release mechanism, dosage form, labeling, or dosing interval can affect whether the product remains eligible under the OTC pathway. Minor inactive-ingredient changes may be simpler, but they still require quality, stability, and labeling assessment.

What is the most attractive private-label opportunity against Delsym?

A retailer-branded 12-hour dextromethorphan suspension with lower sugar, dye-free labeling, a calibrated oral syringe, and competitive pricing offers the clearest opportunity. The product must maintain comparable release and sensory performance.

Are biosimilars relevant to Delsym?

No. Delsym contains a small-molecule cough suppressant complex, not a biologic. Biosimilar approval and interchangeability rules do not apply.

References

1. National Library of Medicine. (n.d.). Delsym 12 hour cough relief: DailyMed drug label. DailyMed. https://dailymed.nlm.nih.gov/

2. U.S. Food and Drug Administration. (n.d.). Over-the-counter medicines. FDA. https://www.fda.gov/drugs/

3. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. FDA. https://www.accessdata.fda.gov/scripts/cder/ob/

4. U.S. Food and Drug Administration. (2023). Over-the-counter monograph M012: Internal analgesic, antipyretic, and antirheumatic drug products. FDA. https://www.accessdata.fda.gov/

5. U.S. Food and Drug Administration. (n.d.). Use caution when giving cough and cold products to kids. FDA. https://www.fda.gov/drugs/ special?